COL18A1 and allergic asthma: Although expression of endostatin has not been described in obstructive airway diseases, treatment with recombinant endostatin prevented airway hyperresponsiveness, airway inflammation and expression of inflammatory mediators in a mouse model of allergic asthma [76].